Literature DB >> 7909371

A mixed micellar formulation suitable for the parenteral administration of taxol.

H Alkan-Onyuksel1, S Ramakrishnan, H B Chai, J M Pezzuto.   

Abstract

Taxol is a promising antitumor agent with poor water solubility. Intravenous administration of a current taxol formulation in a non-aqueous vehicle containing Cremophor EL may cause allergic reactions and precipitation upon aqueous dilution. In this study a novel approach to formulate taxol in aqueous medium for i.v. delivery is described. The drug is solubilized in bile salt (BS)/phospholipid (PC) mixed micelles. The solubilization potential of the mixed micelles increased as the total lipid concentration and the molar ratio of PC/BS increased. Precipitation of the drug upon dilution was avoided by the spontaneous formation of drug-loaded liposomes from mixed micelles. The formulation can be stored in a freeze-dried form as mixed micelles to achieve optimum stability, and liposomes can be prepared by simple dilution just before administration. As judged by a panel of cultured cell lines, the cytotoxic activity of taxol was retained when formulated as a mixed-micellar solution. Further, for the same solubilization potential, the mixed-micellar vehicle appeared to be less toxic than the standard nonaqueous vehicle of taxol containing Cremophor EL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909371     DOI: 10.1023/a:1018943021705

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Taxol. Out of the woods.

Authors:  S M Edgington
Journal:  Biotechnology (N Y)       Date:  1991-10

2.  In vitro and in vivo antitumoral activity of free, and encapsulated taxol.

Authors:  M H Bartoli; M Boitard; H Fessi; H Beriel; J P Devissaguet; F Picot; F Puisieux
Journal:  J Microencapsul       Date:  1990 Apr-Jun       Impact factor: 3.142

3.  A new parenteral emulsion for the administration of taxol.

Authors:  B D Tarr; T G Sambandan; S H Yalkowsky
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

4.  Preclinical safety evaluation of intravenously administered mixed micelles.

Authors:  K Teelmann; B Schläppi; M Schüpbach; A Kistler
Journal:  Arzneimittelforschung       Date:  1984

5.  Mesophase formation during in vitro cholesterol gallstone dissolution: a specific effect of ursodeoxycholic acid.

Authors:  C C Su; J Y Park; W I Higuchi; M H Alkan; O I Corrigan; A F Hofmann; R G Danzinger
Journal:  J Pharm Sci       Date:  1981-06       Impact factor: 3.534

6.  Quasielastic light-scattering studies of aqueous biliary lipid systems. Mixed micelle formation in bile salt-lecithin solutions.

Authors:  N A Mazer; G B Benedek; M C Carey
Journal:  Biochemistry       Date:  1980-02-19       Impact factor: 3.162

7.  Mixed micelles as proliposomes for the solubilization of teniposide.

Authors:  H Alkan-Onyuksel; K Son
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

8.  Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification.

Authors:  D W Shen; A Fojo; J E Chin; I B Roninson; N Richert; I Pastan; M M Gottesman
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

9.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Taxol binds to polymerized tubulin in vitro.

Authors:  J Parness; S B Horwitz
Journal:  J Cell Biol       Date:  1981-11       Impact factor: 10.539

View more
  24 in total

1.  Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Control Release       Date:  2012-01-27       Impact factor: 9.776

2.  Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization.

Authors:  Sang Cheon Lee; Kang Moo Huh; Jaehwi Lee; Yong Woo Cho; Raymond E Galinsky; Kinam Park
Journal:  Biomacromolecules       Date:  2007-01       Impact factor: 6.988

3.  Development of novel chitosan derivatives as micellar carriers of taxol.

Authors:  A Miwa; A Ishibe; M Nakano; T Yamahira; S Itai; S Jinno; H Kawahara
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

4.  Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility.

Authors:  Rui-ling Duan; Xun Sun; Jie Liu; Tao Gong; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-12-20       Impact factor: 6.150

Review 5.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

6.  Novel biodegradable polylactide/poly(ethylene glycol) micelles prepared by direct dissolution method for controlled delivery of anticancer drugs.

Authors:  Liu Yang; Xiaohan Wu; Feng Liu; Yourong Duan; Suming Li
Journal:  Pharm Res       Date:  2009-08-08       Impact factor: 4.200

7.  Influence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-11-13       Impact factor: 3.534

8.  Pharmacokinetics of paclitaxel-containing liposomes in rats.

Authors:  Gerald J Fetterly; Robert M Straubinger
Journal:  AAPS PharmSci       Date:  2003-11-21

9.  Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property.

Authors:  Jaehwi Lee; Sang Cheon Lee; Ghanashyam Acharya; Ching-jer Chang; Kinam Park
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.